Prasugrel is a third-generation thienopyridine P2Y12 inhibitor with faster onset, greater potency, and less inter-patient variability than clopidogrel. The TRITON-TIMI 38 trial demonstrated superior efficacy over clopidogrel in ACS patients undergoing PCI, but with higher bleeding risk. Its single-step hepatic activation avoids the CYP2C19 polymorphism issue seen with clopidogrel.
History of prior stroke or TIA (net clinical harm demonstrated)
The bottom line
Evidence rating strong. Most-documented uses: superior to clopidogrel in reducing ischemic events in acs-pci (triton-timi 38), faster onset of platelet inhibition than clopidogrel, more consistent antiplatelet effect (not affected by cyp2c19 polymorphism). 10 sources indexed (2017–2023), with 4 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Thienopyridine prodrug that requires only a single CYP-mediated hepatic oxidation step (primarily CYP3A4 and CYP2B6) to generate the active metabolite. The active metabolite irreversibly binds to the platelet P2Y12 ADP receptor, blocking ADP-mediated platelet activation and aggregation. Faster and more complete platelet inhibition than clopidogrel, with minimal impact from CYP2C19 polymorphisms.
Class
Antiplatelet Agent (P2Y12 Inhibitor)
Dosing
Dosing & protocol.
Common range
60 mg loading dose, then 10 mg once daily (5 mg daily if <60 kg) for up to 12 months with aspirin (as prescribed by your physician)
Recommended form
Oral tablet
Can be taken with or without food; rapidly absorbed and converted to active metabolite8,10
Safety
Full safety detail.
Side effects
Bleeding (higher rate than clopidogrel, including life-threatening and fatal bleeding)
Bruising
Epistaxis
GI bleeding
Anemia
Rash
Thrombotic thrombocytopenic purpura (TTP, very rare)
Ginkgo biloba inhibits platelet-activating factor and platelet aggregation. Added to prasugrel's potent irreversible P2Y12 inhibition, the antiplatelet effect of ginkgo creates a meaningful additive bleeding risk. Prasugrel already carries a higher bleeding rate than clopidogrel, so additional antiplatelet supplements are especially risky.
Recommendation: Avoid ginkgo biloba while on prasugrel. If you have been combining them, stop the ginkgo and call your prescriber if you notice unusual bruising, nosebleeds, or any sign of bleeding.
Concentrated garlic supplements inhibit platelet aggregation. Combined with prasugrel's potent irreversible P2Y12 inhibition, garlic supplements stack antiplatelet activity and can raise bleeding risk, particularly perioperatively.
Recommendation: Avoid concentrated garlic supplements while on prasugrel, and stop them at least 7 days before any planned surgery. Cooking with garlic is fine.
Fish oil's omega-3 fatty acids reduce platelet thromboxane A2 generation and modestly prolong bleeding time. Added to prasugrel's potent irreversible P2Y12 inhibition, high-dose fish oil (more than 3 g/day EPA+DHA) can additively raise bleeding risk, particularly perioperatively. Prasugrel's bleeding rate is already higher than clopidogrel's.
Recommendation: Keep fish oil dose modest (≤2 g/day combined EPA+DHA) on prasugrel and keep the dose constant. Stop fish oil at least 7 days before any planned surgery.
Nattokinase has fibrinolytic and anticoagulant effects that can stack with prasugrel's potent antiplatelet effect. A case report describes cerebellar hemorrhage after nattokinase was added to aspirin, and human studies show nattokinase can reduce fibrinogen and factors VII and VIII. Combining it with prasugrel may increase bleeding risk, especially after stent placement, stroke, surgery, or in older adults.
Recommendation: Avoid nattokinase while taking prasugrel unless your cardiologist specifically approves it. Do not use nattokinase as a substitute for prescribed antiplatelet therapy. Seek urgent care for severe headache, weakness on one side, black stools, vomiting blood, or bleeding that does not stop.
Shah RP, Shafiq A, Hamza M et al.. Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. The American journal of cardiology. 2023
Ullah W, Ali Z, Sadiq U et al.. Meta-Analysis Comparing the Safety and Efficacy of Prasugrel and Ticagrelor in Acute Coronary Syndrome. The American journal of cardiology. 2020
Sun MT, Huang S, Wiviott SD et al.. Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. The American journal of cardiology. 2020
Xia P, He C, Chen L et al.. Efficacy and safety of prasugrel therapy for intracranial aneurysms with endovascular treatment: A meta-analysis. Journal of the neurological sciences. 2019
Spartalis M, Tzatzaki E, Spartalis E et al.. The role of prasugrel in the management of acute coronary syndromes: a systematic review. European review for medical and pharmacological sciences. 2017
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Prasugrel in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack